Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

December 01, 2015 3:12 AM ET


Company Overview of Maxygen, Inc.

Company Overview

Maxygen, Inc., a biopharmaceutical company, focuses on the discovery and development of protein pharmaceuticals for the treatment of disease and serious medical conditions in the United States. It focuses on developing MAXY-G34 product candidate, a granulocyte colony stimulating factor, for the treatment of chemotherapy-induced neutropenia and acute radiation syndrome. The company was founded in 1996 and is headquartered in San Mateo, California.

411 Borel Avenue

Suite 616

San Mateo, CA 94402

United States

Founded in 1996

3 Employees





Key Executives for Maxygen, Inc.

Executive Chairman of The Board, Chief Executive Officer and Chief Financial Officer
Age: 68
Chief Patent Counsel and Vice President of Intellectual Property
Senior Vice President of Research and Development
Age: 58
Senior Vice President of Danish Operations and Senior Vice President of Global Project Management
General Counsel and Corporate Secretary
Age: 46
Compensation as of Fiscal Year 2015.

Maxygen, Inc. Key Developments

Maxygen, Inc. Announces Final Liquidating Distribution, Payable on About June 30, 2014

Maxygen, Inc. announced that, in accordance with the plan of dissolution approved by its shareholders on August 12, 2013, its Board of Directors has approved a second and final liquidating distribution in the amount of $0.093 per share of common stock. The final liquidating distribution will have a record date of August 29, 2013, which is the date on which the company filed its certificate of dissolution with the Secretary of State of Delaware and closed its stock transfer books. The company will make no further distributions beyond the final liquidating distribution. There is no requirement for stockholders to surrender shares in connection with the final liquidating distribution. Maxygen expects to pay this final liquidating distribution in cash on or about June 30, 2014.

Similar Private Companies By Industry

Company Name Region
Celgene Avilomics Research, Inc. United States
Mytogen, Inc. United States
PhaseRx, Inc. United States
Repairogen Corp. United States
Genpathway, Inc. United States

Recent Private Companies Transactions

No transactions available in the past 12 months.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Maxygen, Inc., please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at